BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36344325)

  • 1. Molecular Imaging of Lymphoma: Future Directions and Perspectives.
    Pomykala KL; Fendler WP; Vermesh O; Umutlu L; Herrmann K; Seifert R
    Semin Nucl Med; 2023 May; 53(3):449-456. PubMed ID: 36344325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG-PET/CT in the management of lymphomas: current status and future directions.
    El-Galaly TC; Villa D; Gormsen LC; Baech J; Lo A; Cheah CY
    J Intern Med; 2018 Oct; 284(4):358-376. PubMed ID: 29989234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography/computed tomography in the management of Hodgkin and B-cell non-Hodgkin lymphoma: An update.
    Juweid ME; Mueller M; Alhouri A; A-Risheq MZ; Mottaghy FM
    Cancer; 2021 Oct; 127(20):3727-3741. PubMed ID: 34286864
    [No Abstract]   [Full Text] [Related]  

  • 4. Diagnostic performance of prospective same-day 18F-FDG PET/MRI and 18F-FDG PET/CT in the staging and response assessment of lymphoma.
    Mistry V; Scott JR; Wang TY; Mollee P; Miles KA; Law WP; Hapgood G
    Cancer Imaging; 2023 Jan; 23(1):11. PubMed ID: 36694244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
    Specht L
    Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Role of Functional Imaging in the Management of Lymphoma.
    Cheson BD; Meignan M
    Curr Oncol Rep; 2021 Nov; 23(12):144. PubMed ID: 34735647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usual and unusual pitfalls of 18F-FDG-PET/CT in lymphoma after treatment: a pictorial review.
    Dubreuil J; Salles G; Bozzetto J; Tordo J; Djaïleb L; Berriolo-Riedinger A; Leenhardt J; Giammarile F; Meignan M; Skanjeti A
    Nucl Med Commun; 2017 Jul; 38(7):563-576. PubMed ID: 28570287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When should FDG-PET be used in the modern management of lymphoma?
    Barrington SF; Mikhaeel NG
    Br J Haematol; 2014 Feb; 164(3):315-28. PubMed ID: 24131306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET/CT: appropriate application in lymphoma.
    Wang X
    Chin Clin Oncol; 2015 Mar; 4(1):4. PubMed ID: 25841711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Lymphoma in children and adolescents].
    Sorge I; Georgi TW; Hirsch FW
    Radiologe; 2021 Jul; 61(7):611-618. PubMed ID: 34160645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter Comparison of Contrast-Enhanced FDG PET/CT and 64-Slice Multi-Detector-Row CT for Initial Staging and Response Evaluation at the End of Treatment in Patients With Lymphoma.
    Gómez León N; Delgado-Bolton RC; Del Campo Del Val L; Cabezas B; Arranz R; García M; Cannata J; González Ortega S; Pérez Sáez MÁ; López-Botet B; Rodríguez-Vigil B; Mateo M; Colletti PM; Rubello D; Carreras JL
    Clin Nucl Med; 2017 Aug; 42(8):595-602. PubMed ID: 28604477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of
    Kaste SC; Snyder SE; Metzger ML; Sandlund JT; Howard SC; Krasin M; Shulkin BL
    J Nucl Med; 2017 Mar; 58(3):419-424. PubMed ID: 27609791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Artificial Intelligence in PET/CT Imaging for Management of Lymphoma.
    Veziroglu EM; Farhadi F; Hasani N; Nikpanah M; Roschewski M; Summers RM; Saboury B
    Semin Nucl Med; 2023 May; 53(3):426-448. PubMed ID: 36870800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond the lymph nodes: FDG-PET/CT in primary extranodal lymphoma.
    Sin KM; Ho SK; Wong BY; Gill H; Khong PL; Lee EY
    Clin Imaging; 2017; 42():25-33. PubMed ID: 27875758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [F-18 fluorodeoxyglucose positron emission tomography in malignant lymphoma].
    Mikosch P
    Wien Med Wochenschr; 2002; 152(11-12):269-75. PubMed ID: 12138654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG-PET/CT in lymphoma.
    Juweid ME
    Methods Mol Biol; 2011; 727():1-19. PubMed ID: 21331925
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Tamayo P; Martín A; Díaz L; Cabrero M; García R; García-Talavera P; Caballero D
    Rev Esp Med Nucl Imagen Mol; 2017; 36(5):312-321. PubMed ID: 28483374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review.
    Kiamanesh Z; Ayati N; Sadeghi R; Hawkes E; Lee ST; Scott AM
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4661-4676. PubMed ID: 35932329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controversies on the prognostic value of interim FDG-PET in advanced-stage Hodgkin lymphoma.
    Adams HJ; Kwee TC
    Eur J Haematol; 2016 Dec; 97(6):491-498. PubMed ID: 27528557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.